Last Updated : September 6, 2022
Details
Generic Name:
tirzepatide
Project Status:
Cancelled
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0751-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Eli Lilly Canada Inc. is requesting reimbursement of tirzepatide, consistent with a subset of the target Health Canada indication, for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
N/A
Indications:
For the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance. • 1 to 3 oral antihyperglycemic agents (any one or combination of metformin, sulfonylurea, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), when diet and exercise plus the baseline treatment does not achieve adequate glycemic control. • basal insulin with or without metformin, when diet and exercise plus basal insulin with or without metformin do not achie...
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | 14-Jul-22 |
| Call for patient/clinician input closed | 02-Sep-22 |
| Clarification: - Patient input submission received from Diabetes Canada | |
| Submission received | 12-Aug-22 |
| Submission accepted | |
| Clarification: - Submission was not accepted for review on 26 Aug 2022 | |
Last Updated : September 6, 2022